Bigfoot Biomedical, a medical device company harnessing the power of artificial intelligence to develop systems designed to automatically and continuously optimize insulin delivery for people living with insulin-requiring diabetes, announced that the company has raised $37 million in the initial tranche of a Series B equity financing. The round is co-led by funds managed by a new investor, Janus Henderson Investors, along with Bigfoot’s largest existing investor, Quadrant Capital Advisors, Inc. Additionally, existing investors Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund and T1D Exchange also participated in the financing. This financing follows a previously announced $36 million Series A financing completed in 2016.
Read more: http://bit.ly/BigfootBiomedical